医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer

2017年10月16日 PM08:30
このエントリーをはてなブックマークに追加


 

ST. HELIER, Jersey

Novocure (NASDAQ: NVCR) announced today five data presentations at the International Associations for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer, October 15 to October 18 in Yokohama, Japan.

“We look forward to having our research on Tumor Treating Fields (TTFields) presented at the world’s largest meeting dedicated to lung cancer and other thoracic malignancies,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. “Lung cancer is the most common cause of cancer death worldwide. TTFields shows promise in multiple solid tumor types, including some of the most aggressive forms of cancer. We are committed to researching TTFields as a treatment for multiple solid tumor types and sharing our findings with the scientific community.”

The following posters will be presented at the IASLC World Conference on Lung Cancer:

Advanced non-small cell lung cancer

(P3.01-088d) TTFields Combined with PD-1 Inhibitors or Docetaxel for 2nd Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) (ID 7563): Phase 3 LUNAR Study. U. Weinberg, O. Farber, M. Giladi, Z. Bomzon, E. Kirson. 9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)

(P3.01-088e) TTFields Delivery to the Brain: An Overview of Computational Studies and Implications When Treating Brain Metastases (ID 8773). S. Levi, Z. Bomzon, A. Naveh, E. Kirson, U. Weinberg. 9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)

Clinical design, statistics and clinical trials

(P3.04-013b) TTFields and Radiosurgery for 1-10 Brain Metastases from NSCLC: The Phase 3 METIS Study (ID 7562). M. Mehta, V. Gondi, M. Ahluwalia, P. Brown. 9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)

Immunology and immunotherapy

(P3.07-013c) Computational Simulations for Investigating Electric Field Distributions When Delivering Tumor Treating Fields (TTFields) to the Lungs (ID 8776). H. Hershkovich, O. Yesharim, N. Urman, A. Naveh, U. Weinberg, E. Kirson, Z. Bomzon U. Weinberg. 9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)

(P3.07-013d) Tumor Treating Fields Induce Immunogenic Cell Death and Enhance Antitumor Effects of Anti-PD1 in NSCLC In-Vivo Models (ID 8952). T. Voloshin, O. Yitzhaki, M. Giladi, N. Kaynan, A. Shteingauz, M. Munster, R. Blat, Y. Porat, R. Schneiderman, E. Zeevi, S. Cahal, A. Itzhaki, E. Kirson, U. Weinberg, Y. Palti. 9:30 a.m. to 4 p.m. JST October 18. (Exhibit Hall, Hall B + C)

About Novocure

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 23, 2017, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171016005152/en/

CONTACT

Media and Investor Contact:
Novocure
Ashley Cordova,
212-767-7558
acordova@novocure.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者